• Novo Nordisk Q1 2026 operating profit rose 65% to DKK 59.62 billion as net sales climbed 24% to DKK 96.82 billion.
• Results were boosted by a provision reversal tied to US 340B; adjusted operating profit fell 15% to DKK 32.86 billion, while adjusted net sales dropped 10% to DKK 70.06 billion.
• Wegovy pill sales reached DKK 2.26 billion, with around 1.3 million total prescriptions in Q1 and weekly prescriptions above 200,000 by week ending April 17.
• Guidance was raised, with 2026 adjusted net sales growth now seen at -4% to -12% and adjusted operating profit growth at -4% to -12%.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Novo Nordisk A/S published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605060131OMX_____CNEWS_EN_GNW1001180204_en) on May 06, 2026, and is solely responsible for the information contained therein.